Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMD) saw a significant decrease in short interest in June. As of June 15th, there was short interest totaling 18,552 shares, a decrease of 79.8% from the May 31st total of 91,823 shares. Based on an average trading volume of 66,646 shares, the short-interest ratio is currently 0.3 days. Currently, 0.2% of the shares of the company are short sold.

Ainos Trading Down 3.9%

Shares of Ainos stock opened at $1.73 on Friday. Ainos has a 1 year low of $1.26 and a 1 year high of $4.50. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.50 and a current ratio of 0.55. The company has a market capitalization of $14.74 million, a P/E ratio of -0.60 and a beta of 2.41. The company’s fifty day moving average is $1.90 and its two-hundred day moving average is $1.79.

Ainos (NASDAQ:AIMD) last announced its earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Ainos currently has an average rating of “Sell”.

Insiders Place Their Bets

In other news, Director Ting-Chuan Lee sold 109,988 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $1.90, for a total value of $208,977.20. Following the completion of the sale, the director directly owned 807,417 shares of the company’s stock, valued at approximately $1,534,092.30. The trade was a 11.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Chun-Jung Tsai sold 27,718 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $1.87, for a total value of $51,832.66. Following the completion of the sale, the director directly owned 658,199 shares of the company’s stock, valued at approximately $1,230,832.13. This trade represents a 4.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have bought 7,800 shares of company stock valued at $15,946 and have sold 179,788 shares valued at $359,247. Corporate insiders own 9.79% of the company’s stock.

Institutional Trading of Ainos

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mariner LLC acquired a new stake in Ainos during the 4th quarter worth approximately $37,000. Two Sigma Investments LP acquired a new position in shares of Ainos in the third quarter valued at approximately $80,000. DRW Securities LLC raised its stake in shares of Ainos by 272.6% during the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after purchasing an additional 48,439 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after purchasing an additional 7,700 shares during the last quarter.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.